Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvacta Group Regulatory News (AVCT)

Share Price Information for Avacta Group (AVCT)

Share Price is delayed by 15 minutes
Get Live Data
70.50    1.00 (1.44%)
Bid:
69.00
Ask:
72.00
Spread: 3.00 (4.348%)
Market Cap: £330.33m
AVCT Live PriceLast checked at - London Stock Exchange

Intraday Avacta Group Share Chart

Holding(s) in Company

28 Jul 2009 17:07

RNS Number : 4339W
Avacta Group PLC
28 July 2009
 



Avacta Group plc

("Avactaor "the Company")

Holdings in Company

TR-1: NOTIFICATION OF MAJOR INTERESTS IN SHARES

1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached:

Avacta Group plc

2. Reason for the notification:

An acquisition or disposal of voting rights

3. Full name of person(s) subject to the notification obligation:

Bainunah Trading Ltd

4. Full name of shareholder(s) (if different from 3.):

5. Date of the transaction (and date on which the threshold is crossed or reached if different):

27 July 2009

6. Date on which issuer notified:

28 July 2009

7. Threshold(s) that is/are crossed or reached:

From 3.16% to 0.818%

8. Notified details:

……………..

A: Voting rights attached to shares

Class/type of shares if possible using the ISIN CODE

Situation previous to the Triggering transaction 

Number of shares

Number of voting Rights 

GB0033519546

36,434,578

36,434,578

Resulting situation after the triggering transaction 

Class/type of shares if possible using the ISIN CODE

Number of shares 

Number of voting rights 

% of voting rights

Direct

Direct 

Indirect 

Direct

Indirect

GB0033519546

9,434,578

9,434,578

0.8186%

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction 

Type of financial instrument

Expiration Date 

Exercise/Conversion Period/ Date 

Number of voting rights that may be acquired if the instrument is exercised/ converted.

% of voting rights

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments 

Resulting situation after the triggering transaction 

Type of financial instrument

Exercise Price

Expiration Date 

Exercise/Conversion Period

Number of voting rights instrument refers to

% of voting rights

Nominal

Delta

 

Total (A+B+C)

Number of voting rights

% of voting rights

9,434,578

0.8186%

9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable (xv):

Proxy Voting:

10. Name of the proxy holder:

……………..

11. Number of voting rights proxy holder will cease to hold:

……………..

12. Date on which proxy holder will cease to hold voting rights:

……………..

13. Additional information:

……………..

14. Contact name:

M. Fielding

15. Contact telephone number:

 07797714409

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLGGGZNVRVGLZM
Date   Source Headline
9th Jul 20267:00 amRNSAccelerated Amortized Payment of Bond Installment
8th Jul 20267:00 amRNSAvacta Appoints Patrick Vink Deputy Chairman
25th Jun 20267:00 amRNSPlatform-Validating Data with Faridoxorubicin
25th Jun 20267:00 amRNSFDA Agreement on Pivotal Trial Design for AVA6000
23rd Jun 20267:00 amRNSResult of AGM
22nd Jun 20267:00 amRNSYear-to-date business update ahead of AGM
5th Jun 20267:00 amRNSOversubscribed Strategic Equity Fundraise of £9m
1st Jun 20263:00 pmRNSBlock Listing - Application to AIM
1st Jun 20267:00 amRNSClinical data on AVA6000 in salivary gland cancers
29th May 20267:00 amRNSPosting of Annual Report and Notice of AGM
29th May 20267:00 amRNSBoard Director Changes
19th May 20267:00 amRNSUnaudited Preliminary Full Year 2025 Results
13th May 20267:00 amRNSNotice of Preliminary Results and Presentation
13th May 20267:00 amRNSIssue of Equity and Total Voting Rights
6th May 20267:00 amRNSPre|CISION® payload release vs approved ADCs
28th Apr 20267:00 amRNSBlock Listing Six Monthly Return
21st Apr 20267:00 amRNSAvacta data AACR underline AVA6103 profile
14th Apr 202611:37 amRNS-RChristina Coughlin - In Vivo 2026 Rising Leader
9th Apr 20267:00 amRNSQ1 2026 Business Update
8th Apr 20267:00 amRNS-RAvacta Announces Science Day 2026
31st Mar 20267:00 amRNSFirst patient treated in Phase 1 trial of AVA6103
27th Mar 20267:00 amRNSResult of Oversubscribed Fundraise
26th Mar 20265:16 pmRNSProposed Fundraise to raise approximately £10m
26th Mar 20264:44 pmRNSIssue of Equity
17th Mar 20267:00 amRNS-RPresentations of pre|CISION® Platform Candidates
17th Mar 20267:00 amRNS-RPresentations of pre|CISION® Platform Candidates
16th Mar 20267:00 amRNSPhase 1 study opening for AVA6103
16th Mar 20267:00 amRNSPhase 1 study opening for AVA6103
24th Feb 20267:00 amRNSPreCISION payload delivery advantage over ADC
18th Feb 20267:00 amRNS-RAvacta to Participate in Conference March 2026
9th Feb 20267:00 amRNSAppointment of CSO
3rd Feb 20267:00 amRNSFaridoxorubicin Program Clinical Updates
21st Jan 20267:00 amRNSFDA Clearance of IND Application for AVA6103
20th Jan 20267:01 amRNSYear-end trading update
20th Jan 20267:00 amRNSAppointment of Nominated Adviser & TVR
18th Dec 20257:00 amRNS-RAvacta reports new AVA6103 pharmacology data
17th Dec 20257:00 amRNSFaridoxorubicin Phase 1b SGC data
8th Dec 20257:00 amRNSPreliminary Data in Faridoxorubicin Phase 1b Trial
3rd Nov 20258:24 amRNSCompletion of Placing and TVR
27th Oct 20255:39 pmRNSBlock Listing Six Monthly Return
27th Oct 20257:00 amRNSAvacta presents preclinical data at AACR-NCI-EORTC
23rd Oct 20255:00 pmRNS-RNotice of Investor Presentation
20th Oct 20257:01 amRNSEquity fundraise of £16 million
20th Oct 20257:00 amRNSAvacta Presents Phase 1a Data for Faridoxorubicin
13th Oct 20257:00 amRNSAvacta to present data at EORTC-NCI-AACR
30th Sep 20257:00 amRNSInterim Half Year Results 2025
15th Sep 20257:00 amRNSNotice of Interim Results
9th Sep 20257:00 amRNS-RShortlisted for AIM Awards Technology of the Year
1st Sep 20257:00 amRNSAvacta completes sale of Coris Bioconcept
29th Aug 20257:00 amRNSAmendments to Convertible Bond + equity fundraise

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.